Presence of a Sporadic Case of Systemic Granulomatosis Syndrome with a CARD15 Mutation  by Kanazawa, Nobuo et al.
Presence of a Sporadic Case of Systemic Granulomatosis
Syndrome with a CARD15 Mutation
To the Editor:
A 27-year-old Japanese man developed multiple lichenoid
papules, fusing into scaly erythematous plaques, over his
entire body (Fig 1a). In infancy he had been diagnosed with
atopic dermatitis and juvenile rheumatoid arthritis. Although
the skin disease had almost disappeared afterwards,
disorder of the joints and associated eyes involvement
had progressively worsened. When we first saw him, he was
almost blind and showed camptodactyly (Fig 1a) with
continuous low-grade fever. Laboratory findings showed
abnormally high levels of C-reactive protein, uric acid,
angiotensin-converting enzyme, and soluble interleukin-2.
The skin biopsy specimen indicated the presence of non-
caseating epithelioid cell granulomas without arteritis (Fig
1b). Although hilar lymphoadenopathy was not apparent on
a chest roentgenogram, the transbronchial lung biopsy
specimen also demonstrated the presence of non-case-
ating granulomas. Sarcoidosis was the prime suspect and
the progression of early-onset disorders of the skin, joints,
and eyes is quite consistent with that of early-onset sarcoi-
dosis (EOS) (Rasmussen, 1981), which has often been
misdiagnosed as juvenile rheumatoid arthritis (Lindsley and
Godfrey, 1985). The disease of our patient, however,
could not be definitely diagnosed as EOS, because active
inflammatory changes of his eyes and joints could no longer
be histologically assessed. There was no family history of
skin, eye, or joint granulomatous disease to suggest Blau
syndrome (BS) (Blau, 1985), a sarcoid-like autosomal domi-
nant disorder that has recently been shown to result from
mutations in the nucleotide-binding domain (NOD) of CARD15
(Miceli-Richard et al, 2001; Wang et al, 2002).
In order to investigate the possibility that CARD15
mutations were associated with the diseases of our patient,
genomic DNA samples were extracted from his peripheral
blood and the skin biopsy specimen, and provided for
sequence analysis. Informed consent was obtained for the
molecular examinations, which were approved by the Ethics
Committee of Kyoto University.
DNA fragments including exon 4 of the CARD15 gene
(exon 3 of GenBank accession number AJ303140), which
covers the NOD, were amplified by polymerase chain
reaction, and their nucleotide sequence was determined.
As a result, one missense mutation in the NOD, a C-to-T
transition at complementary DNA position 1000 resulting in
an R-to-W change at amino acid position 334, was
discovered in both DNA samples from peripheral blood
and skin (Fig 2a, b). The levels of fluorescence intensity of
normal C (blue) and mutated T (red) were almost the same,
and the sequence analysis of subcloned colonies also
showed a 1:1 separation ratio between C and T, indicating
that this mutation occurred in one genomic allele without
chimerism among organs. Surprisingly, this mutation was
exactly the same as that observed in five BS families
(Miceli-Richard et al, 2001; Wang et al, 2002). Furthermore,
this mutation was not recognized in the genomes of his
parents (Fig 2c, d), confirming the sporadic origin of the
mutation.
CARD15, originally reported as NOD2, is a member of
the CED4/APAF1 family of apoptosis regulators, and is
predominantly expressed in monocytes (Ogura et al,
2001b). The gene product is composed of two caspase
recruitment domains (CARDs), NOD and leucine-rich
repeats (LRRs). This domain structure predicts the presence
of NODs, a family of related cytosolic proteins (Inohara et al,
2002). In addition to the regulation of apoptosis, CARD15
protein can recognize bacterial components and activate
host defense through nuclear factor kB (NFkB) activation
(Girardin et al, 2003; Inohara et al, 2003). While mutations in
LRRs of the CARD15 gene are reportedly associated with
Crohn’s disease (Hugot et al, 2001; Ogura et al, 2001a),
three types of missense point mutations in NOD were
discovered in families of BS and related familial granulo-
matosis syndromes (Miceli-Richard et al, 2001; Wang et al,
2002). The mutations in Crohn’s disease cause impairment
of bacterial component-dependent NFkB activation,
whereas those in BS promote such component-indepen-
dent activation of NFkB, providing possible mechanisms of
granuloma formation in septic and aseptic sites, respec-
tively (Chamaillard et al, 2003).
For many years, it has been of interest as to whether BS
and EOS share the same entity or not. The only point with
which one can distinguish BS from EOS would be the
presence of inheritance, but some people consider that
these diseases are the same (Miller, 1986; Blau, 1998) and
there still remains diagnostic confusion (James, 1999). In
the first report of CARD15 mutations in BS, the authors also
examined two EOS patients but could not detect any
mutation, and therefore proposed the different origin of BS
and EOS (Miceli-Richard et al, 2001). In contrast, our patient
is a sporadic case with clinical features resembling those of
EOS and a CARD15 mutation which is exactly the same as
that reported in some BS families. These findings suggest
the possibility that some cases of EOS have a CARD15
Abbreviations: BS, Blau syndrome; CARD, caspase recruitment
domain; EOS, early-onset sarcoidosis; LRR, leucine-rich repeat;
NFkB, nuclear factor kB; NOD, nucleotide-binding oligomerization
domain.
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mutation or that the sporadic BS is present with a CARD15
mutation. So far in Japan, about ten cases of EOS have
been reported, whereas no BS cases have been reported
(Ukae et al, 1994; Sakurai et al, 1997; Yotsumoto et al,
2000). Investigation of CARD15 mutations in these patients
will provide us with more information about the genotype–
phenotype relationship in EOS.
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Figure 1
Gross and histological findings of the patient’s skin. Multiple
lichenoid papules fusing into scaly erythematous plaques on the
patient’s arms (a) are shown. Wrist and finger joints are fixed at the
flexor positions, showing camptodactyly. A section of the skin biopsy
specimen from erythematous plaque was stained with hematoxylin and
eosin (b). Scale bar: 0.1mm.
Figure 2
Sequence analysis of the CARD15 gene. DNA samples were
extracted from the patient’s peripheral blood and skin biopsy specimen
and from his parents’ peripheral blood. Exon 4 of CARD15 gene was
amplified from each DNA sample with polymerase chain reaction using
two sets of primer pairs: 50-TCT GGT TAG GTC CCG TCT TCA C-30
(forward primer) and 50-AGA ACA CGT AGC AGC ACA TGC C-30
(reverse primer), and 50-AGA CTC AGC TTC CCA AGG TCT G-30
(forward primer) and 50-GCT CCC ACA CTT AGC CTT GAT G-30
(reverse primer). Amplified DNA fragments were directly sequenced
and at the same time subcloned into a plasmid vector to determine the
separation ratio of the mutation. Sequence electrophoregrams of the
amplified DNA fragments, derived from (a) the patient’s peripheral
blood and (b) skin and (c) his father’s and (d) mother’s peripheral blood,
are shown.
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